RxDoctor Payments DataLook up a doctor →

Mary Foland, MD

Family Medicine · Anchorage, AKNPI 1871557645

Payments from drug & device makers

$14,993in general payments, 2019–2025

Across 896 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • Novo Nordisk$1K
  • GSK$1K
  • Lilly USA, LLC$1K
  • Astellas Pharma US Inc$999
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$14,971100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,993 in reported general payments places this provider in the 95th percentile of 334 family medicine providers in Alaska.

See all family medicine providers in Alaska

Medicare billing

Part B allowed, 2024
$73,007
Medicare patients
256
Services billed
2,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$65,005
JardianceEmpagliflozin44$50,230
OzempicSemaglutide23$26,651
MyrbetriqMirabegron17$24,417
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$20,485
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$19,506
SynthroidLevothyroxine Sodium165$17,290
FarxigaDapagliflozin Propanediol30$16,928
JanuviaSitagliptin Phosphate26$13,205
Estradiol43$8,484
Pitavastatin Calcium12$4,537
Candesartan Cilexetil22$3,277
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,634
Venlafaxine Hcl ErVenlafaxine Hcl20$2,402
Rosuvastatin Calcium102$1,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$539$65,00553 claims
Boehringer IngelheimJardiance$573$50,23044 claims
AstraZenecaBreztri Aerosphere, Farxiga$2,861$36,43446 claims
Novo NordiskOzempic$1,273$26,65123 claims
Astellas Pharma US IncMyrbetriq$999$24,41717 claims
GSKTrelegy Ellipta$1,149$20,48527 claims
AbbVieSynthroid$2,291$17,290165 claims
MerckJanuvia$318$13,20526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 family medicine providers in Alaska.

Other family medicine in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →